Our Techonology
Proprietary platforms overcoming the limits of traditional proteomics.
KLS™ Platform
Kinome-Wide insight for TPD success. Quantifies over 500 kinases endogenously to predict toxicity and elucidate MoA.
ID-Free AI
Analyzing "dark" MS/MS data to unlock the future of cancer screening and multi-cancer early detection.
Advanced Proteomics
Unrivaled depth and sensitivity via Zero MS Dead Time Analysis and NCFC 2D Separation systems.
Precision at Scale
Industry-leading depth and sensitivity across our platform.
500+
Kinases Quantified
(vs. Industry Avg. ~300)
13k+
Proteins Identified
(vs. Industry Avg. ~7k)
100k+
Phosphopeptides Detected
(vs. Industry Avg. ~40k)
2x
MS Throughput
(vs. Traditional Methods)
Services & Diagnostics
Empowering discovery and clinical insights through advanced proteomic capabilities.
Get in Touch
Service Quotes, Partnerships, and Investor Relations.
Our Office
145 Anam-ro, Seongbuk-gu, Seoul, Republic of Korea